A Phase 1 interventional study of ABBV-932 and Placebo in Generalized Anxiety Disorder (GAD) and Healthy Participants, sponsored by AbbVie. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-01.
Sponsored by AbbVie · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 265 studies in Generalized Anxiety Disorder with a site in United States — 38 open to participants now, 53 under way, 9 of them phase 3. Generalized Anxiety Disorder · United States.
Among the 265 studies in Generalized Anxiety Disorder with a site in United States, this one is the 107th largest by enrollment of the 234 interventional ones that give a count, is one of 10 that started in 2023, is one of 10 in phase 1, and was the 213th registered.
518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.
Browse Generalized Anxiety Disorder studies →38 of the 265 studies in Generalized Anxiety Disorder with a site in United States are open now. Recruiting first, the newest first:
Virginia Polytechnic Institute and State University · Sites in United States
Ages 18–65
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in United States
Ages 18+
Intra-Cellular Therapies, Inc. · Sites in United States
Ages 18+
BTL Industries Ltd. · Sites in United States
Ages 22+
Intra-Cellular Therapies, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 86 Generalized Anxiety Disorder studies recruiting now, 32 (37%) set no upper age limit and 52 (60%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
265 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 32 · Phase 3 51 · Phase 4 28
First in 1991; this study’s year is marked. 10 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 104 is above the median of 83 across 440 interventional studies indexed under Generalized Anxiety Disorder.
Median enrollment 90 across the 234 interventional studies, 220 across the 28 observational. Of the 199 that completed or were terminated, 90 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
83 of 265 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
AbbVie has 8 studies filed under Generalized Anxiety Disorder — fewer than ten, so there is no comparison to draw.
20 of the studies in Generalized Anxiety Disorder with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07123467Phase 3Wayne State UniversityCannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder | 2027-08-31 |
| NCT06846320AbbVieStudy to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | 2026-11 |
| NCT06723158Boston UniversityOral Surgery Virtual Reality Glasses Study | 2026-12 |
| NCT04557891University of California, Los AngelesLow-Intensity Focused Ultrasound Pulsation (LIFUP) for the Treatment of Generalized Anxiety Disorder (GAD) | 2026-12 |
| NCT05467683Jasper A. SmitsCO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy | 2026-12-01 |
Add all 20 to your calendar (.ics) → With an account.
Among the 265 studies in Generalized Anxiety Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective of this study is to assess pharmacokinetics, safety, and tolerability of ABBV-932 in healthy adult participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive ABBV-932 on Day 1 and followed for 30 days.
Drug: ABBV-932
Participants will receive placebo on Day 1 and followed for 30 days.
Drug: Placebo
Participants will receive ABBV-932 on Day 1 in Period 1 under fasting conditions and followed for 30 days. Participants will receive ABBV-932 with food on Day 1 in Period 2 and followed for 30 days.
Drug: ABBV-932
Participants will receive ABBV-932 with food on Day 1 in Period 1 and followed for 30 days. Participants will receive ABBV-932 on Day 1 in Period 2 under fasting conditions and followed for 30 days.
Drug: ABBV-932
Japanese participants will receive ABBV-932 on Day 1 in Period 1 and followed for 30 days.
Drug: ABBV-932
Japanese participants will receive placebo on Day 1 in Period 1 and followed for 30 days.
Drug: Placebo
Han-Chinese participants will receive placebo on Day 1 in Period 1 and followed for 30 days.
Drug: ABBV-932
Oral Capsule
Oral Capsule
Maximum Plasma Concentration (Cmax) of ABBV-932
Cmax of ABBV-932.
Time frame: Up to approximately 5 days
Time to Cmax (Tmax) of ABBV-932
Tmax of ABBV-932.
Time frame: Up to approximately 5 days
Terminal Phase Elimination Rate Constant (Beta) of ABBV-932
Terminal phase elimination rate constant (beta) of ABBV-932.
Time frame: Up to approximately 5 days
Terminal Phase Elimination Half-Life (t1/2) of ABBV-932
Terminal phase elimination half-life of ABBV-932.
Time frame: Up to approximately 5 days
Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of ABBV-932
AUCt of ABBV-932.
Time frame: Up to approximately 5 days
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-932
AUCinf of ABBV-932.
Time frame: Up to approximately 5 days
Maximum Plasma Concentration (Cmax) of DCAR
Cmax of DCAR.
Time frame: Up to approximately 5 days
Time to Cmax (Tmax) of DCAR
Tmax of DCAR.
Time frame: Up to approximately 5 days
Terminal Phase Elimination Rate Constant (Beta) of DCAR
Terminal phase elimination rate constant (beta) of DCAR.
Time frame: Up to approximately 5 days
Terminal Phase Elimination Half-Life (t1/2) of DCAR
Terminal phase elimination half-life of DCAR.
Time frame: Up to approximately 5 days
Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of DCAR
AUCt of DCAR.
Time frame: Up to approximately 5 days
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of DCAR
AUCinf of DCAR.
Time frame: Up to approximately 5 days
Maximum Plasma Concentration (Cmax) of DDCAR
Cmax of DDCAR.
Time frame: Up to approximately 5 days
Time to Cmax (Tmax) of DDCAR
Tmax of DDCAR.
Time frame: Up to approximately 5 days
Terminal Phase Elimination Rate Constant (Beta) of DDCAR
Terminal phase elimination rate constant (beta) of DDCAR.
Time frame: Up to approximately 5 days
Terminal Phase Elimination Half-Life (t1/2) of DDCAR
Terminal phase elimination half-life of DDCAR.
Time frame: Up to approximately 5 days
Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of DDCAR
AUCt of DDCAR.
Time frame: Up to approximately 5 days
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of DDCAR
AUCinf of DDCAR.
Time frame: Up to approximately 5 days
Plan to share: No
Ran from Feb 2023 to primary completion in May 2024, 15 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ABBV-932
Generalized Anxiety Disorder →